drugset / Trial / NCT07092865
A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant
Non-randomizedSingle-groupOpen-labelPrevention
Summary
This study evaluates persistence of the immune response of the adjuvanted RSV vaccine and the safety and immunogenicity following revaccination in adults 18 years of age and above who received lung or kidney transplant.
Timeline
- Start
- 2025-08-06
- Primary completion
- 2027-01-12
- Completion
- 2027-07-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adjuvanted RSVPreF3 vaccine | Vaccine | 1 unknown | Intramuscular |